逸達生物科技 Foresee Pharmaceuticals Co., Ltd.
About Us
Company Profile
Business Model
Board of Directors
Management Team
Scientific Advisory Board
Others
R & D
Pipeline Overview
SIF Pipeline
CAMCEVI(FP-001):Prostate Cancer; Central Precocious Puberty
FP-014:Prostate Cancer
FP-016:Neurology; Psychiatry
Other Research Projects
NCE Pipeline
FP-025 (aderamastat): Cardiac Sarcoidosis
FP-020 (linvemastat): Asthma; COPD; IBD
FP-MMP-12 inhibitor 1: ILD, including IPF
FP-MMP-12 inhibitor 2: Neurology
FP-045 (mirivadelgat): Fanconi Anemia; PH-ILD
FP-ALDH2 Activator 1: CVRM
FP-ALDH2 Activator 2: Neurology
Media
Press Release
Media Library
Investors
Corporate Governance
Corporate Charters
Board of Directors
Others
Material Information
News & Events
Press Releases
Events & Presentations
Financial Information
Financial Results
Monthly Revenues
Sharholder Information
Annual General Meeting
Major Shareholders
FAQs
Investor Contacts
Others
Career
Benefits
Join Us
Contact Us
繁體中文
HOME
繁體中文
HOME
Latest News
Foresee Pharmaceuticals Announces Submission of the NDA to the U.S. FDA for the 3-month Version of CAMCEVI for the Treatment of Advanced Prostate Cancer
Foresee Pharmaceuticals Announces Preliminary Results from a Phase 1 Clinical Trial, Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile of Linvemastat (FP-020)
Foresee Pharmaceuticals Announces Several New Developments Related to its SIF Long-Acting Injectable (LAI) Technologies – Solidifying its Position as a Leader in Complex LAI Products
Foresee Pharmaceuticals Announces First Subject Dosed in its First-in-Human Clinical Trial of FP-020
Foresee Pharmaceuticals Announces Poster Presentation and Participation at the 2024 American Thoracic Society International Conference
Foresee Pharmaceuticals Receives Positive Recommendation from DSMB to Continue the Casppian Study, a Phase 3 Clinical Trial of Leuprolide (FP-001) Injectable Emulsion for the Treatment of Cen
Foresee Pharmaceuticals Announces Publication of Preclinical Data in the European Heart Journal
Foresee Pharmaceuticals to Present at the American Heart Association Annual Meeting Focusing on its ALDH2 activator FP-045 in Pulmonary Hypertension Associated with Interstitial Lung Disease
Foresee Pharmaceuticals Announces First Patient Dosed in the Casppian, Phase 3 Clinical Trial of Leuprolide (FP-001) injectable emulsion, 42 mg for the treatment of Central Precocious Puberty
Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium
Foresee Pharmaceuticals Announces Publication of Preclinical Data in Nature Communications
Foresee Pharmaceuticals Presents Data From its Aderamastat Program at The European Respiratory Society (ERS) International Congress 2023
Foresee Pharmaceuticals Announces FDA Orange Book Listing of New U.S. Patent for CAMCEVI®, Extending Patent Protection to 2039
Foresee Pharmaceuticals Selected for Late-Breaking Oral Presentation on its Aderamastat Phase 2 Study Results at the European Respiratory Society (ERS) International Congress 2023
Foresee Pharmaceuticals Announces Completion of US$42.3 Million Financing
Foresee Pharmaceuticals Presented Poster on MMP-12 inhibitor, FP-020, in Genetic Model of Sarcoidosis at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases
Foresee Pharmaceuticals Announces Poster Presentation and Participation at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs)
Press Release
Pipeline Overview
Financial Information
Join Us